this company is now a substantial holder ...., page-3

Working in medicine tells me that if copaxone is a $3B drug to teva, the cardiovascular drugs msb are developing will be worth many multiples of that alone. In a typical general practice I have 2 patients with MS but probably up to 100 to 200 with some form of cardiovascular issue. There would also be similar if not greater numbers with type 2 diabetes all using often multiple therapies costing thousands of dollars a year. Add the patients with intervertebral disc disease etc etc and copaxone looks to be a minnow. Msb is currently valued at less than $3B and hence I firmly believe it is undervalued by significant multiples. It will be Australia's greatest contribution to medicine and if these therapies are as impressive as they've been so far then it will truly introduce medicine to a new paradigm.